ENANTA PHARMACEUTICALS, INC (ENTA) Scorecard
- 2026-Q2: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2026-Q1: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2025-Q4: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2025-Q3: Total return Win; Revenue growth Lose; EPS growth Lose.
38/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 3 wins, 9 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q21/3 |
WinENTA / S&P 15.44% / 15.20% |
LoseENTA / S&P 0.70% / 15.00% |
LoseENTA / S&P -43.98% / 50.40% |
| 2026-Q10/3 |
LoseENTA / S&P -19.91% / -4.33% |
LoseENTA / S&P 7.37% / 11.30% |
LoseENTA / S&P -42.73% / 27.70% |
| 2025-Q41/3 |
WinENTA / S&P 31.75% / 2.65% |
LoseENTA / S&P 0.58% / 9.00% |
LoseENTA / S&P -35.15% / 13.40% |
| 2025-Q31/3 |
WinENTA / S&P 58.33% / 8.12% |
LoseENTA / S&P -3.42% / 4.61% |
LoseENTA / S&P -29.93% / 13.45% |
| 2025-Q21/3 |
WinENTA / S&P 36.96% / 10.94% |
LoseENTA / S&P -9.94% / 4.83% |
LoseENTA / S&P -20.73% / 10.63% |
| 2025-Q11/3 |
WinENTA / S&P -4.00% / -4.27% |
LoseENTA / S&P -11.55% / 4.98% |
LoseENTA / S&P -27.24% / 10.57% |
| 2024-Q40/3 |
LoseENTA / S&P -44.50% / 2.41% |
LoseENTA / S&P -9.55% / 5.25% |
LoseENTA / S&P -24.54% / 6.15% |
| 2024-Q30/3 |
LoseENTA / S&P -20.12% / 5.89% |
LoseENTA / S&P -14.61% / 5.89% |
LoseENTA / S&P -13.97% / 6.11% |
| 2024-Q20/3 |
LoseENTA / S&P -25.72% / 4.28% |
LoseENTA / S&P -10.71% / 5.38% |
LoseENTA / S&P -13.63% / 5.12% |
| 2024-Q11/3 |
WinENTA / S&P 85.55% / 10.56% |
LoseENTA / S&P -10.22% / 5.71% |
LoseENTA / S&P 4.35% / 5.59% |
| 2023-Q41/3 |
LoseENTA / S&P -15.76% / 11.69% |
LoseENTA / S&P -10.32% / 6.81% |
WinENTA / S&P 12.71% / 7.78% |
| 2023-Q31/3 |
LoseENTA / S&P -47.80% / -3.27% |
LoseENTA / S&P -8.07% / 7.52% |
WinENTA / S&P 7.78% / -5.03% |
| 2023-Q21/3 |
LoseENTA / S&P -47.08% / 8.74% |
LoseENTA / S&P -9.87% / 9.50% |
WinENTA / S&P 7.68% / -8.57% |
| 2023-Q11/3 |
LoseENTA / S&P -13.07% / 7.50% |
LoseENTA / S&P -11.34% / 10.77% |
WinENTA / S&P 8.33% / -15.69% |
| 2022-Q41/3 |
LoseENTA / S&P -10.31% / 7.56% |
LoseENTA / S&P -11.70% / 11.88% |
WinENTA / S&P 16.87% / -17.99% |
| 2022-Q32/3 |
WinENTA / S&P 9.73% / -4.88% |
LoseENTA / S&P -11.24% / 13.47% |
WinENTA / S&P 51.15% / -1.41% |
| 2022-Q21/3 |
LoseENTA / S&P -33.59% / -16.10% |
LoseENTA / S&P -7.94% / 13.71% |
WinENTA / S&P 40.87% / 11.04% |
| 2022-Q11/3 |
LoseENTA / S&P -4.81% / -4.60% |
LoseENTA / S&P -2.76% / 15.97% |
WinENTA / S&P 50.00% / 42.23% |
| 2021-Q41/3 |
WinENTA / S&P 31.63% / 11.03% |
LoseENTA / S&P -8.53% / 15.00% |
LoseENTA / S&P 72.32% / 96.40% |
| 2021-Q32/3 |
WinENTA / S&P 29.08% / 0.58% |
LoseENTA / S&P -20.74% / 10.77% |
WinENTA / S&P 113.66% / 69.42% |
| 2021-Q20/3 |
LoseENTA / S&P -10.77% / 8.55% |
LoseENTA / S&P -35.31% / 6.58% |
LoseENTA / S&P -5300.00% / 51.81% |
| 2021-Q11/3 |
WinENTA / S&P 17.15% / 6.17% |
LoseENTA / S&P -46.46% / -1.06% |
LoseENTA / S&P -428.57% / 7.39% |
| 2020-Q40/3 |
LoseENTA / S&P -8.04% / 12.15% |
LoseENTA / S&P -45.90% / -3.72% |
LoseENTA / S&P -278.40% / -33.42% |
| 2020-Q30/3 |
LoseENTA / S&P -8.82% / 8.93% |
LoseENTA / S&P -40.31% / -2.04% |
LoseENTA / S&P -182.43% / -27.10% |
| 2020-Q20/3 |
LoseENTA / S&P -2.37% / 20.54% |
LoseENTA / S&P -32.08% / -0.46% |
LoseENTA / S&P -97.41% / -27.11% |
| 2020-Q11/3 |
WinENTA / S&P -16.75% / -19.60% |
LoseENTA / S&P -24.84% / 3.47% |
LoseENTA / S&P -69.97% / -14.75% |
| 2019-Q40/3 |
LoseENTA / S&P 2.83% / 9.07% |
LoseENTA / S&P -21.19% / 5.36% |
LoseENTA / S&P -60.87% / 2.99% |
| 2019-Q30/3 |
LoseENTA / S&P -28.80% / 1.70% |
LoseENTA / S&P -0.69% / 5.02% |
LoseENTA / S&P -36.21% / 0.21% |
| 2019-Q20/3 |
LoseENTA / S&P -11.66% / 4.30% |
LoseENTA / S&P 2.67% / 6.64% |
LoseENTA / S&P -24.08% / 8.65% |
| 2019-Q13/3 |
WinENTA / S&P 34.86% / 13.65% |
WinENTA / S&P 41.30% / 8.12% |
WinENTA / S&P 40.23% / 14.29% |
| 2018-Q42/3 |
LoseENTA / S&P -17.12% / -13.52% |
WinENTA / S&P 82.68% / 9.05% |
WinENTA / S&P 133.90% / 18.23% |
| 2018-Q32/3 |
LoseENTA / S&P -26.26% / 7.71% |
WinENTA / S&P 100.97% / 10.21% |
WinENTA / S&P 278.26% / 19.06% |
| 2018-Q22/3 |
WinENTA / S&P 43.25% / 3.43% |
WinENTA / S&P 442.05% / 9.03% |
LoseENTA / S&P -480.37% / 14.46% |
| 2018-Q12/3 |
WinENTA / S&P 37.88% / -0.76% |
WinENTA / S&P 258.47% / 7.68% |
LoseENTA / S&P -485.51% / 12.46% |
| 2017-Q42/3 |
WinENTA / S&P 25.38% / 6.64% |
WinENTA / S&P 159.77% / 7.03% |
LoseENTA / S&P -454.00% / 13.82% |
| 2017-Q32/3 |
WinENTA / S&P 30.07% / 4.48% |
WinENTA / S&P 16.48% / 5.68% |
LoseENTA / S&P -17.86% / 17.57% |
| 2017-Q21/3 |
WinENTA / S&P 16.82% / 3.09% |
LoseENTA / S&P -55.78% / 4.83% |
LoseENTA / S&P -171.33% / 17.74% |
| 2017-Q10/3 |
LoseENTA / S&P -8.06% / 6.07% |
LoseENTA / S&P -47.18% / 3.67% |
LoseENTA / S&P -140.83% / 13.32% |
| 2016-Q41/3 |
WinENTA / S&P 25.89% / 3.82% |
LoseENTA / S&P -61.89% / 2.09% |
LoseENTA / S&P -115.29% / 7.05% |
| 2016-Q31/3 |
WinENTA / S&P 20.68% / 3.85% |
LoseENTA / S&P -45.13% / 0.20% |
LoseENTA / S&P -72.62% / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | ENTA total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 64.29% | 20.78% |
| Annualized return | 64.29% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | ENTA total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -75.79% | 83.14% |
| Annualized return | -24.70% | 12.86% |
10Y · 2016-09-01 to 2026-08-27
| Metric | ENTA total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -37.33% | 319.30% |
| Annualized return | -4.57% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |